Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock: Insider George Milne, Jr. Sells 30,000 Shares

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director George Milne, Jr. sold 30,000 shares of the business’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $27.70, for a total value of $831,000.00. Following the transaction, the director directly owned 782,881 shares of the company’s stock, valued at $21,685,803.70. This trade represents a 3.69% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Amylyx Pharmaceuticals Price Performance

Shares of AMLX stock traded down $0.61 on Wednesday, hitting $27.43. 2,056,628 shares of the company’s stock were exchanged, compared to its average volume of 1,658,016. The company has a 50 day moving average of $29.98 and a 200 day moving average of $20.80. The stock has a market cap of $3.06 billion, a P/E ratio of -19.18 and a beta of -0.10. Amylyx Pharmaceuticals, Inc. has a 12 month low of $10.83 and a 12 month high of $41.14.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). Sell-side analysts predict that Amylyx Pharmaceuticals, Inc. will post -1.48 EPS for the current fiscal year.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Large investors have recently modified their holdings of the business. BlackRock Inc. bought a new position in Amylyx Pharmaceuticals during the 2nd quarter worth $158,534,000. GSA Capital Partners LLP bought a new stake in shares of Amylyx Pharmaceuticals in the 2nd quarter valued at about $705,000. Elmind Capital LP acquired a new stake in shares of Amylyx Pharmaceuticals in the second quarter valued at about $2,011,520. Dimensional Fund Advisors LP increased its stake in shares of Amylyx Pharmaceuticals by 17.1% in the first quarter. Dimensional Fund Advisors LP now owns 903,192 shares of the company’s stock valued at $12,544,000 after buying an additional 131,944 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Amylyx Pharmaceuticals during the second quarter worth about $12,949,000. Institutional investors own 95.84% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Mizuho increased their price objective on shares of Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the company an “outperform” rating in a research note on Tuesday, August 18th. Citigroup upped their price target on shares of Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Wolfe Research upgraded Amylyx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 17th. Robert W. Baird boosted their price objective on Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 19th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Wednesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Amylyx Pharmaceuticals has an average rating of “Buy” and a consensus target price of $38.86.

Amylyx Pharmaceuticals Company Profile